A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: neutrophil lymphocyte ratio/albumin ratio

Qiang Zhao; Sheng Chen; Ji-Feng Feng

doi:10.18632/oncotarget.21989

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: neutrophil lymphocyte ratio/albumin ratio

Qiang Zhao, Sheng Chen and Ji-Feng Feng _

PDF | HTML | How to cite

Oncotarget. 2017; 8:103535-103542. https://doi.org/10.18632/oncotarget.21989

Metrics: PDF 1216 views | HTML 2091 views | ?

Abstract

Qiang Zhao1,2, Sheng Chen1,2 and Ji-Feng Feng1,2

1Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, P.R.China

2Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, P.R. China

Correspondence to:

Ji-Feng Feng, email: [email protected], [email protected]

Keywords: esophageal squamous cell carcinoma, c-reactive protein, neutrophil lymphocyte ratio, cancer-specific survival, prognosis

Received: July 10, 2017 Accepted: September 23, 2017 Published: October 20, 2017

ABSTRACT

Background: We initially proposed a novel inflammation-based prognostic index, named neutrophil lymphocyte ratio/albumin ratio (NLR/Alb), for predicting the postoperative survival in esophageal squamous cell carcinoma (ESCC).

Materials and methods: A retrospective study of 329 cases with resectable ESCC was included. The optimal cut-off values were evaluated by X-tile program. The 5-year cancer-specific survival (CSS) was calculated by Kaplan–Meier method. Cox regression analyses were performed to evaluate the prognostic factors.

Results: The optimal cut-off value was 0.1 for NLR/Alb according to the X-tile program. There was a significantly better 5-year CSS in patients with NLR/Alb ≤ 0.1 than patients with NLR/Alb > 0.1 (39.1% vs. 11.0%, P < 0.001). According to multivariate analyses, NLR/Alb (P = 0.001) was an independent prognostic factor.

Conclusions: The NLR/Alb is a novel and usefull predictive factor in patients with ESCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21989

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: neutrophil lymphocyte ratio/albumin ratio

Abstract